85553-53-3

Usage

Uses

Used in Pharmaceutical Industry:
3-(2-Pyridyl)benzaldehyde is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its unique chemical structure allows it to be a key component in the creation of various medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical industry, 3-(2-Pyridyl)benzaldehyde is used as an intermediate in the production of agrochemicals, playing a crucial role in the development of pesticides and other agricultural chemicals that are essential for crop protection and yield enhancement.
Used in Fragrance Industry:
3-(2-Pyridyl)benzaldehyde is used as a fragrance ingredient due to its strong and pleasant odor. Its distinctive scent makes it a popular choice for incorporation into perfumes, colognes, and other scented products.
Used in Fine Chemicals Industry:
As an intermediate in the synthesis of fine chemicals, 3-(2-Pyridyl)benzaldehyde contributes to the production of specialty chemicals that are used in various applications, such as dyes, coatings, and other industrial processes.
Used in Medicinal Chemistry Research:
3-(2-Pyridyl)benzaldehyde is used in medicinal chemistry research for its potential applications in drug discovery and development. Its unique chemical properties allow researchers to explore its interactions with biological systems and its potential as a therapeutic agent.

InChI:InChI=1/C12H9NO/c14-9-10-4-3-5-11(8-10)12-6-1-2-7-13-12/h1-9H

Upstream product

• 109-04-6 2-bromo-pyridine 
• 87199-16-4 3-Formylphenylboronic acid 
• 3132-99-8 m-bromobenzoic aldehyde 
• 17997-47-6 2-tri-n-butylstannylpyridine 
• 142-08-5 2-hydroxypyridin 
• 1008-89-5 2-phenylpyridine 
• 75-25-2 Bromoform 
• 497-19-8 sodium carbonate 
• 73183-34-3 bis(pinacol)diborane 
• 17789-14-9 3-(1,3-dioxolan-2-yl)-phenylbromide 

Downstream Products

• 1334336-34-3 C₁₈H₁₅NO 
• 98061-41-7 2-(3-hydroxymethylphenyl)pyridine 
• 1440513-11-0 1-(2-oxazolinyl)-3-(2-pyridyl)benzene 
• 98061-20-2 3-pyridin-2-yl-benzoic acid methyl ester 
• 4350-51-0 3-(pyridine-2-yl)benzonitrile 
• 1092657-35-6 2-(3-(chloromethyl)phenyl)pyridine 

Relevant academic research and scientific papers

Twist to Boost: Circumventing Quantum Yield and Dissymmetry Factor Trade-Off in Circularly Polarized Luminescence

Circularly polarized luminescence (CPL) enables promising applications in asymmetric photonics. However, the performances of CPL molecules do not yet meet the requirements of these applications. The shortcoming originates from the trade-off in CPL between the photoluminescence quantum yield (PLQY) and the photoluminescence dissymmetry factor (gPL). In this study, we developed a molecular strategy to circumvent this trade-off. Our approach takes advantage of the strong propensity of [Pt(N^C^N)Cl], where the N^C^N ligand is 1-(2-oxazoline)-3-(2-pyridyl)phenylate, to form face-to-face stacks. We introduced chiral substituents, including (S)-methyl, (R)- and (S)-isopropyl, and (S)-indanyl groups, into the ligand framework. This asymmetric control induces torsional displacements that give homohelical stacks of the Pt(II) complexes. X-ray single-crystal structure analyses for the (S)-isopropyl Pt(II) complex reveal the formation of a homohelical dimer with a Pt···Pt distance of 3.48 ?, which is less than the sum of the van der Waals radii of Pt. This helical stack elicits the metal-metal-to-ligand charge-transfer (MMLCT) transition that exhibits strong chiroptical activity due to the electric transition moment making an acute angle to the magnetic transition moment. The PLQY and gPL values of the MMLCT phosphorescence emission of the (S)-isopropyl Pt(II) complex are 0.49 and 8.4 × 10-4, which are improved by factors of ca. 6 and 4, respectively, relative to the values of the unimolecular emission (PLQY, 0.078; gPL, 2.4 × 10-4). Our photophysical measurements for the systematically controlled Pt(II) complexes reveal that the CPL amplifications depend on the chiral substituent. Our investigations also indicate that excimers are not responsible for the enhanced chiroptical activity. To demonstrate the effectiveness of our approach, organic electroluminescence devices were fabricated. The MMLCT emission devices were found to exhibit simultaneous enhancements in the external quantum efficiency (EQE, 9.7%) and the electroluminescence dissymmetry factor (gEL, 1.2 × 10-4) over the unimolecular emission devices (EQE, 5.8%; gEL, 0.3 × 10-4). These results demonstrate the usefulness of using the chiroptically active MMLCT emission for achieving an amplified CPL.

Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy

In anti-tumour therapy, the toll-like receptor 2/4 (TLR2/4) signalling pathway has been a double-edged sword. TLR2/4 agonists are commonly considered adjuvants for immune stimulation, whereas TLR2/4 antagonists demonstrate more feasibility for anti-tumour therapy under specific chronic inflammatory situations. In individuals with cancer retaliatory proliferation and metastasis after surgery, blocking the TLR2/4 signalling pathway may produce favourable prognosis for patients. Therefore, here, we developed a small-molecule co-inhibitor that targets the TLR2/4 signalling pathway. After high-throughput screening of a compound library containing 14 400 small molecules, followed by hit-to-lead structural optimisation, we finally obtained the compound TX-33, which has effective inhibitory properties against the TLR2/4 signalling pathways. This compound was found to significantly inhibit multiple pro-inflammatory cytokines released by RAW264.7 cells. This was followed by TX-33 demonstrating promising efficacy in subsequent anti-tumour experiments. The current results provide a novel understanding of the role of TLR2/4 in cancer and a novel strategy for anti-tumour therapy.

2-(aryl (azacycloalkane-1-yl) methyl) phenol derivatives and uses thereof

The invention discloses 2-(aryl (azacycloalkane-1-yl) methyl) phenol derivatives and application thereof, and belongs to the technical field of medicines. The invention provides a compound shown in a formula I or pharmaceutically acceptable salt thereof. The series of compounds have good inhibitory activity on the histone demethylase KDM4 family in vitro, the median inhibitory concentration (IC50) of most molecules on KDM4D is less than 500 nM, and the compounds have good inhibitory effect on proliferation of various human tumor cell strains in vitro, so that the series of compounds provide a new effective choice for developing targeted histone demethylase KDM4D drugs and preparing drugs for treating and/or preventing cancers and reproductive system diseases, and have good application prospects.

Preparation method of meta-aromatic aldehyde (by machine translation)

The method, uses an aromatic compound as a raw material, to prepare,bromocarbon, ruthenium catalyst, base and a solvent, wherein the solvent is acetonitrile or, dioxane, which is used as an acylating reagent; to obtain m-substituted aromatic aldehyde; by stirring heating temperature to 1,4 - reaction;hour, separation product in the presence of an alkali, additive, solvent, catalyst. 110 - 130 °C, and a solvent is directly added to the reaction device to obtain a meta-substituted aromatic aldehyde. 20 - 25, The method is convenient and low in cost, by using cheap and C - H easily C - H available, carbon tribromide as an acylating agent under. the ruthenium catalysis action. and a solvent. (by machine translation)

Ruthenium-Catalyzed meta-Selective CAr-H Bond Formylation of Arenes

The meta-CAr-H bond formylation of arenes has been achieved using CHBr3 as a formyl source in the presence of [Ru(p-cym)(OAc)2] as a catalyst. This method provides efficient access to the preparation of various meta-substituted aromatic compounds, such as alcohols, ethers, amines, nitriles, alkenes, halogens, carboxylic acids, and their derivatives, through transformation of the versatile formyl group. Furthermore, mechanistic studies show that the key active species is a pentagonal ruthenacycle complex.

Method for preparing meta-position alkenyl aromatic compound

The invention discloses a method for preparing a meta-position alkenyl aromatic compound. The meta-position alkenyl aromatic compound is prepared from a meta-position formyl aromatic compound and diethyl benzylphosphonate through a reaction, and the reaction comprises steps of directly adding the meta-position formyl aromatic compound, the diethyl benzylphosphonate, ammonium acetate, iodine, peroxytert-butanol, sodium carbonate and ethanol into a reaction device, performing stirring and heating to a temperature of 45-55 DEG C, performing the reaction for 7-9 hours, and separating products, soas to obtain the meta-position alkenyl aromatic compound. By adopting the method, the meta-position alkenyl aromatic compound can be conveniently and rapidly synthesized.

Preparation method of meta-position cyano-aromatic compound

The invention provides a preparation method of a meta-position cyano-aromatic compound. The meta-position cyano-aromatic compound is obtained by performing reaction on a meta-position formyl-aromaticcompound serving as a raw material and ammonium acetate. The preparation method comprises the following steps: directly adding the meta-position formyl-aromatic compound, the ammonium acetate, iodine,tert-butanol hydrogen peroxide, sodium carbonate and ethanol into a reaction device, stirring and heating to 45 to 55 DEG C, performing reaction for 7 to 9 hours and separating products to obtain themeta-position cyano-aromatic compound. Through the reaction, the meta-position cyano-aromatic compound can be obtained conveniently and rapidly.

2-catalyzed directed N -Boc amidation of arenes "on water"

Rhodium(III) catalysis "on water" is effective for directed C-H amidation of arenes. The catalytic process is promoted by OH groups present on the hydrophobic water surface and is inefficient in all (most) common organic solvents investigated so far. In the presence of easily prepared tert-butyl 2,4-dinitrophenoxycarbamate, a new and stable nitrene source, the "on water" reaction can efficiently provide the desired N-Boc-aminated products with good functional group tolerance.

Synthesis of new bioorganometallic Ir- and Rh-complexes having β-lactam containing ligands

The synthesis (and full spectroscopic and crystallographic characterization) of new classes of bioorganometallic Ir- and Rh-complexes having β-lactam containing ligands has been achieved in three steps starting from simple precursors. The procedure for preparing these bioorganometallic compounds uses β-lactams having a phenylpyridyl moiety attached to the C4, N1 or C4 and N1 positions simultaneously, and a directed C-H metal-insertion, in the presence of (MCp*Cl2)2 (M = Ir, Rh). Enantiomerically pure 2-azetidinones can be transformed into diastereomeric (at the metal) mixtures of enantiopure metalla-2-azetidinones. Bimetallic 2-azetidinones are also accessible by this approach. The insertion of electron-poor alkynes into the M-C bond of the bioorganometallic complex occurs regioselectively and in excellent yields. Overall, the sequence imine-β-lactam-metalla-β-lactam is a versatile and efficient full methodology to prepare and functionalize unprecedented, novel Ir- and Rh-complexes having β-lactam containing ligands.

Synthesis and characterization of Sant-75 derivatives as Hedgehog-pathway inhibitors

Sant-75 is a newly identified potent inhibitor of the hedgehog pathway. We designed a diversity-oriented synthesis program, and synthesized a series of Sant-75 analogues, which lays the foundation for further investigation of the structure-activity relationship of this important class of hedgehog-pathway inhibitors.